Drug Profile
AD 114
Alternative Names: AD 114; i-bodiesLatest Information Update: 29 Jul 2020
Price :
$50
*
At a glance
- Originator AdAlta
- Developer AdAlta; Lonza; University of Sydney
- Class Antibodies; Antifibrotics; Eye disorder therapies; Proteins; Recombinant proteins; Urologics
- Mechanism of Action CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Fibrosis; Idiopathic pulmonary fibrosis; Kidney disorders; Retinal disorders
Most Recent Events
- 29 Jul 2020 Discontinued - Preclinical for Idiopathic pulmonary fibrosis in Australia (unspecified route) (AdAlta website, July 2020)
- 29 Jul 2020 Discontinued for Fibrosis in Switzerland, Australia (Parenteral) (AdAlta website, July 2020)
- 29 Jul 2020 Discontinued for Kidney disorders in Australia (unspecified route) (AdAlta website, July 2020)